Table 2.

Comparison of outcomes after transplant between two eras, overall and by intensity of the conditioning regimen.

	Frequency of outcomes among all patients			Frequency of outcomes among patients who received myeloablative conditioning therapy			Frequency of outcomes among patients who received reduced intensity conditioning therapy
	2003- 2007 (n=1148)	2013- 2017 (n=1131)	Adjusted HR (95% CI, p- value)	2003- 2007 (n=891)	2013- 2017 (n=748)	Adjusted HR (95% CI, p-value)	2003- 2007 (n=257)	2013- 2017 (n=383)	Adjusted HR (95% CI, p- value)
Day-200 non-relapse mortality	181 (16%)*	127 (11%)	0.66 (0.48-0.89, p=0.008)	144 (16%)	84 (11%)	0.60 (0.45-0.82)	37 (14%)*	43 (11%)	0.65 (0.41–1.05)
Relapse or progression	348†	244	0.76 (0.61-0.94, p=0.011)	261	153	0.74 (0.59-0.92)	87	96	0.78 (0.56-1.08)
Relapse-related mortality	307	186	0.69 (0.54-0.87, p=0.002)	230	115	0.63 (0.49-0.81)	77	71	0.66 (0.45-0.96)
Overall morality	653†	418	0.66 (0.56-0.78, p<0.001)	480	263	0.65 (0.55-0.78)	173	15	0.67 (0.52-0.86)

^*These numbers are smaller than those previously reported for the 2003-2007 cohort (1). Upon further review, five patients who received reduced intensity conditioning had relapsed before day-200.

^†These numbers are larger than those previously reported for the 2003-2007 cohort, reflecting the extended period of time during which patients were at risk for relapse/progression and mortality.